Linda McAllister has joined Arbor Vita as vice president of diagnostics.
McAllister previously served as director of technology management at Roche Diagnostics. In the past she also was director of clinical genetics at Celera Diagnostics and program manager of genotyping at Affymetrix.
She received her BS in biology and chemistry from the California Institute of Technology and a PhD in neurosciences and an MD from Stanford University Medical School.
Illumina this week announced the appointment of Joel McComb as senior vice president and general manager of the company's Life Sciences Business Unit and Gregory Heath as senior vice president and general manager of the company's Diagnostics Business Unit.
McComb joins Illumina from GE Healthcare where he held a number of executive positions including his most recent position as president of the Interventional Medicine Business. Prior to this role, he was president of Life Sciences Discovery Systems.
In his new position as Illumina's general manager of life sciences, McComb is responsible for managing all products and services related to the research market, namely the BeadArray, BeadXpress, and Genome Analyzer sequencing product lines.
Heath joins Illumina from Roche Molecular Systems where he held a number of senior executive positions, including head of clinical genomics, senior vice president of global product marketing, senior vice president of global marketing and business development, and most recently, senior vice president of global business.
In his new position as general manager of diagnostics, Heath is responsible for managing Illumina's emerging diagnostics business, specifically overseeing the development of diagnostic content for the BeadXpress system, and ultimately for Illumina's sequencing products.
As part of its effort to induce McComb and Heath to join the company, Illumina has granted options to purchase 200,000 and 150,000 shares of Illumina's common stock to McComb and Heath, respectively.
These options have the following terms: an exercise price equal to the closing fair market value of Illumina's common stock on the grant date, a ten-year term and vesting over five years with 20 percent of each option vesting one year from the grant date and 1/60th of each option vesting monthly thereafter. The grant date for these options is March 17, 2008.